UBS Maintains Buy on Repligen, Raises Price Target to $225
UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $195 to $225.
An expert investor-watcher thinks Repligen is a good company and believes it could be worth more money in the future. When smart analysts raise their price targets, it's a hint they see reasons to feel more hopeful about that company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.